The presence of MSI in a tumor has important implications for cancer treatment. MSI-high cancers tend to have a higher mutational burden, making them more likely to respond to immunotherapy, particularly checkpoint inhibitors like pembrolizumab. Identifying MSI can thus guide personalized treatment strategies.